The 48th annual conference of the European Association for the Study of the Liver.

An evaluation of sustained virologic response with sofosbuvir plus daclatasvir, with or without ribavirin, in sufferers with HCV genotype 1 who failed telaprevir or boceprevir previously. An interview with Dr ChhatwalUsing HIV medicines to take care of AMD: an interview with Dr Tag YoungUsing breath testing to diagnose liver diseases: an interview with Larry Cohen ‘Bristol-Myers Squibb includes a longstanding commitment to viral hepatitis and provides been at the forefront of the evolving science in both hepatitis B and C,’ said Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Development and Research, Bristol-Myers Squibb.There exists a tremendous need for novel therapies that exceed VEGF to target the tumor blood circulation.’ Related StoriesMeat-rich diet may increase kidney tumor riskNew findings reveal association between colorectal cancer tumor and melanoma medication treatmentCrucial change in one DNA base predisposes children to aggressive type of cancerIn a phase 1, first-in-human clinical research, patients with advanced-stage tumors were treated with multiple ascending dosages of ACE-041, to judge the security and pharmacokinetics of ACE-041. This research also explored antitumor activity of ACE-041. Summary of interim results provided: ACE-041 subcutaneously injected once every three weeks is generally well-tolerated Common side effects include gentle or moderate peripheral edema, fatigue, nausea, headaches, anorexia, and anemia.